EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Tofacitinib in Ulcerative Colitis: Beyond Biologics?

Prajna Anirvan, Suprabhat Giri iD

Inflammatory Bowel Diseases · 2024

DOI: 10.1093/ibd/izad308 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Prajna Anirvan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Kalinga Gastroenterology Foundation, Cuttack, India. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Biological Products, Pyrimidines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeBiological ProductsPyrimidinesHumansBiological FactorsPiperidines

Substanzen

Biological ProductstofacitinibBiological FactorsPiperidinesPyrimidines

Autor:innen und Institutionen

  • Kalinga Gastroenterology Foundation, Cuttack, India.
  • Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Bhubaneswar, India.

ORCID-Profile: Suprabhat Giri

Zitieren

APA

Anirvan, P., & Giri, S. (2024). Tofacitinib in Ulcerative Colitis: Beyond Biologics?. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad308

Vancouver

Anirvan P, Giri S. Tofacitinib in Ulcerative Colitis: Beyond Biologics?. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad308

BibTeX
@article{Anirvan2024,
  author = {Anirvan, Prajna and Giri, Suprabhat},
  title = {Tofacitinib in Ulcerative Colitis: Beyond Biologics?},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  doi = {10.1093/ibd/izad308}
}
Kostenlos starten →